About the Company
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $REGN News
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the ...
Regeneron accused of ‘fraudulent’ drug-pricing reporting for eye drug Eylea
The Department of Justice on Wednesday accused drug maker Regeneron Pharmaceuticals Inc. of fraudulent practices related the ...
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron ...
Regeneron Fraudulently Inflated Medicare Reimbursement On Drug: Feds
The federal government has accused Regeneron Pharmaceuticals Inc., which is based in Tarrytown, of fraudulently inflating ...
Regeneron Pharmaceuticals Faces False Claims Act Allegations Over Deceptive Drug Pricing Reports
The United States has filed a complaint under the False Claims Act (FCA) against Regeneron Pharmaceuticals Inc. (Regeneron), ...
US Intensifies Drug Discount Debate in Latest Regeneron Lawsuit
New Justice Department allegations that Regeneron Pharmaceuticals Inc. artificially inflated Medicare reimbursement rates on ...
Regeneron Pharmaceuticals Inc REGN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Federal Circuit Dismisses Appeals in Regeneron v. Mylan (Aflibercept) BPCIA Litigation
As we previously reported, trial in Regeneron Pharmaceutical, Inc.’s BPCIA case against Mylan Pharmaceuticals Inc. and Biocon Biologics, Inc. (collectively, “the Biocon Defendants”) regarding the ...
Regeneron Pharmaceuticals Stock (NASDAQ:REGN), Analyst Ratings, Price Targets, Predictions
$899.16 16.22% Truist Securities ...
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at ...
Regeneron Pharmaceuticals, Inc. (REGN) Stock: A Look at the Analyst Recommendations
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has a higher price-to-earnings ratio of 26.48x compared to its average ratio. REGN has 36-month beta value of 0.15. Analysts have mixed views on the ...
Loading the latest forecasts...